UCB SA - Asset Resilience Ratio

Latest as of June 2026: 0.15%

UCB SA (UCB) has an Asset Resilience Ratio of 0.15% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is UCB SA's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€31.00 Million

≈ $36.24 Million USD Cash + Short-term Investments

Total Assets

€20.63 Billion

≈ $24.12 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2000–2025)

This chart shows how UCB SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see UCB SA total assets.

Liquid Assets Composition Over Time

This chart breaks down UCB SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of UCB SA's assets are long-term investments to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€31.00 Million	0.15%
Total Liquid Assets	€31.00 Million	0.15%

Asset Resilience Insights

Limited Liquidity: UCB SA maintains only 0.15% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

UCB SA Industry Peers by Asset Resilience Ratio

Compare UCB SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Revolution Medicines Inc NASDAQ:RVMD	Biotechnology	72.23%
Abivax SA PA:ABVX	Biotechnology	2.34%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
SOLENO THERAPEUT. DL-001 F:6XC	Biotechnology	41.74%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Annual Asset Resilience Ratio for UCB SA (2000–2025)

The table below shows the annual Asset Resilience Ratio data for UCB SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	1.21%	€219.00 Million ≈ $256.03 Million	€18.16 Billion ≈ $21.23 Billion	+0.15pp
2024-12-31	1.06%	€184.00 Million ≈ $215.12 Million	€17.35 Billion ≈ $20.28 Billion	+0.37pp
2023-12-31	0.70%	€108.00 Million ≈ $126.26 Million	€15.54 Billion ≈ $18.17 Billion	-0.38pp
2022-12-31	1.07%	€170.00 Million ≈ $198.75 Million	€15.87 Billion ≈ $18.55 Billion	+0.30pp
2021-12-31	0.77%	€110.00 Million ≈ $128.60 Million	€14.21 Billion ≈ $16.61 Billion	-4.51pp
2020-12-31	5.29%	€704.00 Million ≈ $823.05 Million	€13.32 Billion ≈ $15.57 Billion	-3.64pp
2019-12-31	8.93%	€989.00 Million ≈ $1.16 Billion	€11.08 Billion ≈ $12.95 Billion	+8.76pp
2018-12-31	0.16%	€17.00 Million ≈ $19.87 Million	€10.51 Billion ≈ $12.29 Billion	+0.02pp
2017-12-31	0.14%	€14.00 Million ≈ $16.37 Million	€9.92 Billion ≈ $11.59 Billion	-0.31pp
2016-12-31	0.45%	€46.00 Million ≈ $53.78 Million	€10.21 Billion ≈ $11.94 Billion	+0.14pp
2015-12-31	0.31%	€34.00 Million ≈ $39.75 Million	€10.96 Billion ≈ $12.81 Billion	+0.30pp
2014-12-31	0.01%	€1.00 Million ≈ $1.17 Million	€10.15 Billion ≈ $11.86 Billion	0.00pp
2013-12-31	0.01%	€1.00 Million ≈ $1.17 Million	€9.76 Billion ≈ $11.41 Billion	-0.08pp
2012-12-31	0.09%	€8.00 Million ≈ $9.35 Million	€9.36 Billion ≈ $10.94 Billion	-0.33pp
2011-12-31	0.41%	€38.00 Million ≈ $44.43 Million	€9.18 Billion ≈ $10.73 Billion	-0.27pp
2010-12-31	0.68%	€61.00 Million ≈ $71.32 Million	€8.97 Billion ≈ $10.49 Billion	+0.10pp
2009-12-31	0.58%	€53.00 Million ≈ $61.96 Million	€9.12 Billion ≈ $10.66 Billion	+0.55pp
2008-12-31	0.03%	€3.00 Million ≈ $3.51 Million	€9.52 Billion ≈ $11.13 Billion	-0.97pp
2007-12-31	1.00%	€96.00 Million ≈ $112.23 Million	€9.55 Billion ≈ $11.17 Billion	-6.45pp
2004-12-31	7.45%	€400.36 Million ≈ $468.06 Million	€5.37 Billion ≈ $6.28 Billion	-4.17pp
2003-12-31	11.62%	€359.05 Million ≈ $419.77 Million	€3.09 Billion ≈ $3.61 Billion	-4.44pp
2002-12-31	16.05%	€420.73 Million ≈ $491.88 Million	€2.62 Billion ≈ $3.06 Billion	+2.83pp
2001-12-31	13.22%	€339.05 Million ≈ $396.39 Million	€2.56 Billion ≈ $3.00 Billion	+1.63pp
2000-12-31	11.59%	€266.93 Million ≈ $312.07 Million	€2.30 Billion ≈ $2.69 Billion	--

pp = percentage points

About UCB SA

BR:UCB Belgium Biotechnology

Market Cap

$46.88 Billion

€40.10 Billion EUR

Market Cap Rank

#646 Global

#4 in Belgium

Share Price

€210.30

Change (1 day)

-0.14%

52-Week Range

€196.50 - €285.40

All Time High

€285.40